The highest number of PRIMPOL deficient tumours was observed in breast cancer patients diagnosed with invasive breast cancer (1.7%; 14 out of 817), consisting of invasive lobular carcinoma or invasive ductal carcinoma, or a mixed group (42). Here, PRIMPOL is linked to invasive ductal breast carcinoma.